Potential cytostatic drug GS-9219 is a novel lipophilic prodrug of cyprPMEDAP,in vivo releasing the active compound PMEG in a two-step process.GS-9219 has shown a substantial therapeutic potential in treatment of spontaneous non-Hodgkin's lymphoma